BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

BioStock: Curasight's rights issue subscription period has commenced

2025-05-06 14:28:49

Curasight is currently conducting a DKK 100 million rights issue, with the subscription period closing on May 16. Having secured DKK 47 million in pre-subscriptions and guarantees, plus a DKK 18 million renegotiated loan facility, the company aims to advance in parallel its uTRACE diagnostic and uTREAT therapeutic platforms for cancers such as prostate cancer and glioblastoma.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/curasights-rights-issue-subscription-period-has-commenced/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Vem äger bolaget?

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden